Dithiolethiones for cancer chemoprevention: Where do we stand?

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3470-3479

  Zhang, Yuesheng ^a   Munday, Rex ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b RUAKURA RESEARCH CENTRE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DITHIOLE 2 THIONE; 3H 1,2 DITHIOLE 3 ONE; 3H 1,2 DITHIOLE 3 THIONE; 4 CHLORO 5 METHYL 3H 1,2 DITHIOLE 3 THIONE; 4 ETHYL 3H 1,2 DITHIOLE 3 THIONE; 4 METHYL 5 (2 PYRAZINYL) 3H 1,2 DITHIOLE 3 ONE; 4 METHYL 5 PYRAZINYL 3H 1,2 DITHIOLE 3 ONE; 4 METHYL 5 PYRAZINYL 3H 1,2 DITHIOLE 3 THIONE; 4 PHENYL 3H 1,2 DITHIOLE 3 THIONE; 4,5 DIMETHYL 3H 1,2 DITHIOLE 3 THIONE; 4,5,6,7 TETRAHYDROBENZO[C] 1,2 DITHIOLE 3 THIONE; 5 (4 HYDROXYPHENYL) 3H 1,2 DITHIOLE 3 THIONE; 5 (4 METHOXYPHENYL) 3H 1,2 DITHIOLE 3 THIONE; 5 ETHYL 3H 1,2 DITHIOLE 3 THIONE; 5 METHYL 3H 1,2 DITHIOLE 3 THIONE; 5 PHENYL 3H 1,2 DITHIOLE 3 THIONE; 5 TERT BUTYL 3H 1,2 DITHIOLE 3 THIONE; 5,4 METHYL 3H 1,2 DITHIOLE 3 THIONE; 5,6 DIHYDROCYCLOPENTA[C] 1,2 DITHIOLE 3 (4H)THIONE; 7 METHYL 6,8 BIS(METHYLTHIO)H PYRROLO[1,2]PYRAZINE; DITHIOL DERIVATIVE; DRUG METABOLITE; ENZYME; OLTIPRAZ; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

ANGIOSARCOMA; BLADDER CANCER; BREAST CANCER; BRONCHIAL DYSPLASIA; BRONCHUS DISEASE; CANCER CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; COLON CANCER; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INDUCTION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; HUMAN; KIDNEY CANCER; LIMB PAIN; LIVER CANCER; LUNG CANCER; NONHUMAN; PANCREAS CANCER; PARESTHESIA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SKIN TINGLING; STOMACH CANCER; STRUCTURE ACTIVITY RELATION; TISSUE SPECIFICITY; TRACHEA CANCER;

ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; PYRAZINES; THIONES;

EID: 56249128623     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0625     Document Type: Review

References (96)

1. Barbaglia GA. Ueber den Sulfovaleraldehyd. Ber Dtsch Chem Ges 1884;17:2654-5.
2. Lüttringhaus A, König HB, Böttcher B. Über Trithione II. Konstitution und neue Bildungsweisen. Liebigs Ann Chem 1948;560:201-14.
3. Lozac'h N, Vialle J. The chemistry of the 1,2-dithiole ring. In: Kharasch H, Meyers CY, editors. The chemistry of organic sulfur compounds (volume 2). Pergamon Press; 1966. p. 257-85.
4. Epstein JB, Decoteau WE, Wilkinson A. Effect of Sialor in treatment of xerostomia in Sjogren's syndrome. Oral Surg Oral Med Oral Pathol 1983;56:495-9.
5. Ansher SS, Dolan P, Bueding E. Chemoprotective effects of two dithiolthiones and of butylhydroxyanisole against carbon tetrachloride and acetaminophen toxicity. Hepatology 1983;3:932-5.
6. Bella H, Rahim AG, Mustafa MD, Ahmed MA, Wasfi S, Bennett JL. Oltipraz-antischistosomal efficacy in Sudanese infected with Schistosoma mansoni. Am J Trop Med Hyg 1982;31:775-8.
7. Ansher SS, Dolan P, Bueding E. Biochemical effects of dithiolthiones. Food Chem Toxicol 1986;24:405-15.
8. Wattenberg LW, Bueding E. Inhibitory effects of 5-(2-pyrazinyl)-4-methyl- 1,2-dithiol-3-thione (oltipraz) on carcinogenesis induced by benzo[a]pyrene, diethylnitrosamine and uracil mustard. Carcinogenesis 1986;7:1379-81.
9. 1 binding to DNA in vivo in rats fed phenolic antioxidants, ethoxyquin and a dithiothione. Carcinogenesis 1985;6:759-63.
10. Steele VE, Moon RC, Lubet RA, et al. Preclinical efficacy evaluation of potential chemopreventive agents in animal carcinogenesis models: methods and results from the NCI Chemoprevention Drug Development Program. J Cell Biochem Suppl 1994;20:32-54.
11. Izzotti A, Balansky RM, D'Agostini F, et al. Modulation of biomarkers by chemopreventive agents in smoke-exposed rats. Cancer Res 2001;61:2472-9.
12. 1-induced preneoplastic foci in a rat model of hepatic tumorigenesis. Carcinogenesis 1993;14:2423-5.
13. Rao CV, Rivenson A, Katiwalla M, Kelloff GJ, Reddy BS. Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res 1993;53:2502-6.
14. Ruggeri BA, Robinson C, Angeles T, Wilkinson JT, Clapper ML. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. Clin Cancer Res 2002;8:267-74.
15. Crowell JA, Page JG, Rodman LE, et al. Chronic toxicity studies of 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione, a potential chemopreventive agent. Fundam Appl Toxicol 1997;35:9-21.
16. Munday R. Toxicity of thiols and disulphides: involvement of free-radical species. Free Radic Biol Med 1989;7:659-73.
17. Stohs SJ, Lawson TA, Anderson L, Bueding E. Effects of oltipraz, BHA, ADT and cabbage on glutathione metabolism, DNA damage and lipid peroxidation in old mice. Mech Ageing Dev 1986;37:137-45.
18. Davies MH, Blacker AM, Schnell RC. Dithiolthione-induced alterations in hepatic glutathione and related enzymes in male mice. Biochem Pharmacol 1987;36:568-70.
19. O'Dwyer PJ, Szarka CE, Yao KS, et al. Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz. J Clin Invest 1996;98:1210-7.
20. Szarka CE, Yao KS, Pfeiffer GR, et al. Chronic dosing of oltipraz in people at increased risk for colorectal cancer. Cancer Detect Prev 2001;25:352-61.
21. Jacobson LP, Zhang BC, Zhu YR, et al. Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol Biomarkers Prev 1997;6:257-65.
22. Archer S. The chemotherapy of schistosomiasis. Annu Rev Pharmacol Toxicol 1985;25:485-508.
23. 1 by oltipraz in residents of Qidong, People's Republic of China. J Natl Cancer Inst 1999;91:347-54.
24. Kelley MJ, Glaser EM, Herndon JE II, et al. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiol Biomarkers Prev 2005;14:892-9.
25. Buetler TM, Gallagher EP, Wang C, Stahl DL, Hayes JD, Eaton DL. Induction of phase I and phase II drug-metabolizing enzyme mRNA, protein, and activity by BHA, ethoxyquin, and oltipraz. Toxicol Appl Pharmacol 1995;135:45-57.
26. Kensler TW, Egner PA, Dolan PM, Groopman JD, Roebuck BD. Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4- methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiol-3-thiones and 1,2-dithiol-3-ones. Cancer Res 1987;47:4271-7.
27. Iida K, Itoh K, Kumagai Y, et al. Nrf2 is essential for the chemopreventive efficacy of oltipraz against urinary bladder carcinogenesis. Cancer Res 2004;64:6424-31.
28. Ramos-Gomez M, Kwak MK, Dolan PM, et al. Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad Sci U S A 2001;98:3410-5.
29. Ramos-Gomez M, Dolan PM, Itoh K, Yamamoto M, Kensler TW. Interactive effects of nrf2 genotype and oltipraz on benzo[a]pyrene-DNA adducts and tumor yield in mice. Carcinogenesis 2003;24:461-7.
30. Kwak MK, Wakabayashi N, Itoh K, Motohashi H, Yamamoto M, Kensler TW. Modulation of gene expression by cancer chemopreventive dithiolethiones through the Keap1-Nrf2 pathway. Identification of novel gene clusters for cell survival. J Biol Chem 2003;278:8135-45.
31. Dinkova-Kostova AT, Holtzclaw WD, Kensler TW. The role of Keap1 in cellular protective responses. Chem Res Toxicol 2005;18:1779-91.
32. Kensler TW, Groopman JD, Sutter TR, Curphey TJ, Roebuck BD. Development of cancer chemopreventive agents: oltipraz as a paradigm. Chem Res Toxicol 1999;12:113-26.
33. Velayutham M, Villamena FA, Fishbein JC, Zweier JL. Cancer chemopreventive oltipraz generates superoxide anion radical. Arch Biochem Biophys 2005;435:83-8.
34. Jia Z, Zhu H, Trush MA, Misra HP, Li Y. Generation of superoxide from reaction of 3H-1,2-dithiole-3-thione with thiols: implications for dithiolethione chemoprotection. Mol Cell Biochem 2008;307:185-91.
35. Huang HC, Nguyen T, Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. Proc Natl Acad Sci U S A 2000;97:12475-80.
36. Jaiswal AK. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin. Biochemistry 1991;30:10647-53.
37. Yao KS, O'Dwyer PJ. Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. Biochem Pharmacol 2003;66:15-23.
38. Auyeung DJ, Kessler FK, Ritter JK. Mechanism of rat UDP- glucuronosyltransferase 1A6 induction by oltipraz: evidence for a contribution of the aryl hydrocarbon receptor pathway. Mol Pharmacol 2003;63:119-27.
39. Langouët S, Furge LL, Kerriguy N, Nakamura K, Guillouzo A, Guengerich FP. Inhibition of human cytochrome P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its derivatives, and sulforaphane. Chem Res Toxicol 2000;13:245-52.
40. 1 metabolism in human hepatocytes in primary culture. Cancer Res 1995;55:5574-9.
41. Langouët S, Mahéo K, Berthou F, et al. Effects of administration of the chemoprotective agent oltipraz on CYP1A and CYP2B in rat liver and rat hepatocytes in culture. Carcinogenesis 1997;18:1343-9.
42. Le Ferrec E, Ilyin G, Mahéo K, et al. Differential effects of oltipraz on CYP1A and CYP2B in rat lung. Carcinogenesis 2001;22:49-55.
43. 1 excretion in rat urine during dietary intervention with oltipraz. Carcinogenesis 1996;17:1385-8.
44. Sofowora GG, Choo EF, Mayo G, Shyr Y, Wilkinson GR. In vivo inhibition of human CYP1A2 activity by oltipraz. Cancer Chemother Pharmacol 2001;47:505-10.
45. 1 biotransformation in rat liver: implications for human chemointervention. Cancer Res 1996;56:2306-13.
46. Le Ferrec E, Lagadic-Gossmann D, Rauch C, et al. Transcriptional induction of CYP1A1 by oltipraz in human Caco-2 cells is aryl hydrocarbon receptor- and calcium-dependent. J Biol Chem 2002;277:24780-7.
47. Miao W, Hu L, Kandouz M, Batist G. Oltipraz is a bifunctional inducer activating both phase I and phase II drug-metabolizing enzymes via the xenobiotic responsive element. Mol Pharmacol 2003;64:346-54.
48. Kensler TW, Groopman JD, Eaton DL, Curphey TJ, Roebuck BD. Potent inhibition of aflatoxin-induced hepatic tumorigenesis by the monofunctional enzyme inducer 1,2-dithiole-3-thione. Carcinogenesis 1992;13:95-100.
49. 14C-oltipraz in animals. Pharmacokinetics in mice, rats and monkeys. Comparison of the biotransformation in the infected mouse and in the schistosomes. Arzneimittelforschung 1985;35:1431-6.
50. O'Dwyer PJ, Szarka C, Brennan JM, Laub PB, Gallo JM. Pharmacokinetics of the chemopreventive agent oltipraz and of its metabolite M3 in human subjects after a single oral dose. Clin Cancer Res 2000;6:4692-6.
51. Egner PA, Kensler TW, Prestera T, et al. Regulation of phase 2 enzyme induction by oltipraz and other dithiolethiones. Carcinogenesis 1994;15:177-81.
52. De Long MJ, Dolan P, Santamaria AB, Bueding E. 1,2-Dithiol-3-thione analogs: effects on NAD(P)H:quinone reductase and glutathione levels in murine hepatoma cells. Carcinogenesis 1986;7:977-80.
53. O'Dwyer PJ, Clayton M, Halbherr T, Myers CB, Yao K. Cellular kinetics of induction by oltipraz and its keto derivative of detoxication enzymes in human colon adenocarcinoma cells. Clin Cancer Res 1997;3:783-91.
54. Ko MS, Lee SJ, Kim JW, Lim JW, Kim SG. Differential effects of the oxidized metabolites of oltipraz on the activation of CCAAT/enhancer binding protein-beta and NF-E2-related factor-2 for GSTA2 gene induction. Drug Metab Dispos 2006;34:1353-60.
55. Bieder A, Decouvelaere B, Gaillard C, et al. Comparison of the metabolism of oltipraz in the mouse, rat and monkey and in man. Distribution of the metabolites in each species. Arzneimittelforschung 1983;33:1289-97.
56. Velayutham M, Muthukumaran RB, Sostaric JZ, McCraken J, Fishbein JC, Zweier JL. Interactions of the major metabolite of the cancer chemopreventive drug oltipraz with cytochrome c: a novel pathway for cancer chemoprevention. Free Radic Biol Med 2007;43:1076-85.
57. Velayutham M, Villamena FA, Navamal M, Fishbein JC, Zweier JL. Glutathione-mediated formation of oxygen free radicals by the major metabolite of oltipraz. Chem Res Toxicol 2005;18:970-5.
58. Bouthillier L, Charbonneau M, Brodeur J. Assessment of the role of glutathione conjugation in the protection afforded by anethol dithiolthione against hexachloro-1,3-butadiene-induced nephrotoxicity. Toxicol Appl Pharmacol 1996;139:177-85.
59. Lubet RA, Steele VE, Eto I, Juliana MM, Kelloff GJ, Grubbs CJ. Chemopreventive efficacy of anethole trithione, N-acetyl-L- cysteine, miconazole and phenethylisothiocyanate in the DMBA-induced rat mammary cancer model. Int J Cancer 1997;72:95-101.
60. Reddy BS, Rao CV, Rivenson A, Kelloff G. Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res 1993;53:3493-8.
61. Khanna S, Sen CK, Roy S, Christen MO, Packer L. Protective effects of anethole dithiolethione against oxidative stress-induced cytotoxicity in human Jurkat T cells. Biochem Pharmacol 1998;56:61-9.
62. Christen MO, Fackir L, Jore D. Use of linoleic acid radiolysis for assay of antioxidant action of anethole dithiolethione. Methods Enzymol 1995;252:324-31.
63. Mansuy D, Sassi A, Dansette PM, Plat M. A new potent inhibitor of lipid peroxidation in vitro and in vivo, the hepatoprotective drug anisyldithiolthione. Biochem Biophys Res Commun 1986;135:1015-21.
64. Lam S, MacAulay C, le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-9.
65. 14C-trithioparamethoxyphenylpropene in mice. Scand J Dent Res 1985;93:249-52.
66. Masoud AN, Bueding E. Identification and quantitation of a metabolite of anethol dithiolthione in rat and mouse urine using high-performance liquid chromatography. J Chromatogr 1983;276:111-9.
67. 1-induced hepatic toxicity as short-term screen of cancer chemopreventive dithiolethiones. Fundam Appl Toxicol 1996;32:250-9.
68. Prochaska HJ, Santamaria AB. Direct measurement of NAD(P)H:quinone reductase from cells cultured in microtiter wells: a screening assay for anticarcinogenic enzyme inducers. Anal Biochem 1988;169:328-36.
69. Fahey JW, Dinkova-Kostova AT, Stephenson KK, Talalay P. The "Prochaska" microtiter plate bioassay for inducers of NQO1. Methods Enzymol 2004;382:243-58.
70. Doherty GP, Leith MK, Wang X, Curphey TJ, Begleiter A. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents. Br J Cancer 1998;77:1241-52.
71. Begleiter A, Leith MK, Doherty GP, Digbya TJ, Pan S. Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumor cell lines. Biochem Pharmacol 2001;61:955-64.
72. Munday R, Zhang Y, Munday CM, Li J. Structure-activity relationships in the induction of phase II enzymes by derivatives of 3H-1,2-dithiole-3- thione in rats. Chem Biol Interact 2006;160:115-22.
73. Maxuitenko YY, Libby AH, Joyner HH, et al. Identification of dithiolethiones with better chemopreventive properties than oltipraz. Carcinogenesis 1998;19:1609-15.
74. Munday R, Munday CM. Induction of phase II enzymes by 3H-1,2-dithiole-3-thione: dose-response study in rats. Carcinogenesis 2004;25:1721-5.
75. Roebuck BD, Curphey TJ, Li Y, et al. Evaluation of the cancer chemopreventive potency of dithiolethione analogs of oltipraz. Carcinogenesis 2003;24:1919-28.
76. Brown AP, Morrissey RL, Tolhurst TA, Crowell JA, Levine BS. Oral toxicity of 1,2-dithiole-3-thione, a potential cancer chemopreventive agent, in the rat. Int J Toxicol 2000;19:375-81.
77. Kwak MK, Huang B, Chang H, Kim JA, Kensler TW. Tissue specific increase of the catalytic subunits of the 26S proteasome by indirect antioxidant dithiolethione in mice: enhanced activity for degradation of abnormal protein. Life Sci 2007;80:2411-20.
78. Andringa G, Jongenelen CA, Halfhide L, Drukarch B. The thiol antioxidant 1,2-dithiole-3-thione stimulates the expression of heat shock protein 70 in dopaminergic PC12 cells. Neurosci Lett 2007;416:76-81.
79. Munday R, Mhawech-Fauceglia P, Munday CM, et al. Inhibition of urinary bladder carcinogenesis by broccoli sprouts. Cancer Res 2008;68:1593-600.
80. Tang L, Zhang Y. Isothiocyanates in the chemoprevention of bladder cancer. Curr Drug Metab 2004;5:193-201.
81. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994;14:5-11.
82. Rao CV, Rivenson A, Zang E, Steele V, Kelloff G, Reddy BS. Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5]pyridine-induced lymphoma formation by oltipraz. Cancer Res 1996;56:3395-8.
83. Rao CV, Tokomo K, Kelloff G, Reddy BS. Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis 1991;12:1051-5.
84. Begleiter A, Sivananthan K, Curphey TJ, Bird RP. Induction of NAD(P)H quinone:oxidoreductase1 inhibits carcinogen-induced aberrant crypt foci in colons of Sprague-Dawley rats. Cancer Epidemiol Biomarkers Prev 2003;12:566-72.
85. Wargovich MJ, Chen CD, Jimenez A, et al. Aberrant crypts as a biomarker for colon cancer: evaluation of potential chemopreventive agents in the rat. Cancer Epidemiol Biomarkers Prev 1996;5:355-60.
86. Liu T, Mokuolu AO, Rao CV, Reddy BS, Holt PR. Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology 1995;109:1167-72.
87. 1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res 1991;51:5501-6.
88. Bolton MG, Muñoz A, Jacobson LP, et al. Transient intervention with oltipraz protects against aflatoxin-induced hepatic tumorigenesis. Cancer Res 1993;53:3499-504.
89. Primiano T, Egner PA, Sutter TR, Kelloff GJ, Roebuck BD, Kensler TW. Intermittent dosing with oltipraz: relationship between chemoprevention of aflatoxin-induced tumorigenesis and induction of glutathione S-transferases. Cancer Res 1995;55:4319-24.
90. Kensler TW, Davidson NE, Egner PA, et al. Mechanisms of chemoprotection against aflatoxin-induced hepatocarcinogenesis by oltipraz. In: Nygaard OF, Upton AC, editors. Anticarcinogenesis and radiation protection 2. New York: Plenum Press; 1991. p. 315-22.
91. Sharma S, Gao P, Steele VE. The chemopreventive efficacy of inhaled oltipraz particulates in the B[a]P-induced A/J mouse lung adenoma model. Carcinogenesis 2006;27:1721-7.
92. Son HY, Nishikawa A, Furukawa F, et al. Organ-dependent modifying effects of oltipraz on N-nitrosobis(2-oxopropyl)amine (BOP)-initiation of tumorigenesis in hamsters. Cancer Lett 2000;153:211-8.
93. Clapper ML, Wood M, Leahy K, Lang D, Miknyoczki S, Ruggeri BA. Chemopreventive activity of oltipraz against N-nitrosobis(2-oxopropyl)- amine (BOP)-induced ductal pancreatic carcinoma development and effects on survival of Syrian golden hamsters. Carcinogenesis 1995;16:2159-65.
94. Moon RC, Rao KVN, Detrisac CJ, Kelloff GJ, Steele VE, Doody LA. Chemoprevention of respiratory tract neoplasia in the hamster by oltipraz, alone and in combination. Int J Oncol 1994;4:661-7.
95. Nishikawa A, Tanakamura Z, Furukawa F, et al. Chemopreventive activity of oltipraz against induction of glandular stomach carcinogenesis in rats by N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 1998;19:365-8.
96. Fahey JW, Haristoy X, Dolan PM, et al. Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci U S A 2002;99:7610-5.